dc.contributor.author |
Deepak, Vishwa
|
|
dc.contributor.author |
Kasonga, Abe E.
|
|
dc.contributor.author |
Kruger, Marlena C.
|
|
dc.contributor.author |
Coetzee, Magdalena
|
|
dc.date.accessioned |
2015-06-25T09:14:27Z |
|
dc.date.available |
2015-06-25T09:14:27Z |
|
dc.date.issued |
2015-06 |
|
dc.description.abstract |
Bone loss diseases are often associated with increased receptor activator of NF-κB ligand (RANKL)-induced osteoclast formation. Compounds that can attenuate RANKL-mediated osteoclast formation are of great biomedical interest. Eugenol, a phenolic constituent of clove oil possesses medicinal properties; however, its anti-osteoclastogenic potential is unexplored hitherto. Here, we found that eugenol dose-dependently inhibited the RANKL-induced multinucleated osteoclast formation and TRAP activity in RAW264.7 macrophages. The underlying molecular mechanisms included the attenuation of RANKL-mediated degradation of IκBα and subsequent activation of NF-κB pathway. Furthermore, increase in phosphorylation and activation of RANKL-induced mitogen-activated protein kinase pathways (MAPK) was perturbed by eugenol. RANKL-induced expression of osteoclast-specific marker genes such as TRAP, cathepsin K (CtsK) and matrix metalloproteinase-9 (MMP-9) was remarkably downregulated by eugenol. These findings provide the first line of evidence that eugenol mediated attenuation of RANKL-induced NF-κB and MAPK pathways could synergistically contribute to the inhibition of osteoclast formation. Eugenol could be developed as therapeutic agent against diseases with excessive osteoclast activity. |
en_ZA |
dc.description.embargo |
2016-06-30 |
en_ZA |
dc.description.librarian |
hb2015 |
en_ZA |
dc.description.sponsorship |
The Vice Chancellor’s Postdoctoral Research Fellowship and Institute for
Food, Nutrition and Well-being, University of Pretoria. |
en_ZA |
dc.description.uri |
http://informahealthcare.com/journal/cts |
en_ZA |
dc.identifier.citation |
Deepak, V, Kasonga, A, Kruger, MC & Coetzee, M 2015, 'Inhibitory effects of eugenol on RANKL-induced osteoclast formation via attenuation of NF-kappa B and MAPK pathways', Connective Tissue Research, vol. 56, no. 3, pp. 195-203. |
en_ZA |
dc.identifier.issn |
0300-8207 (print) |
|
dc.identifier.issn |
1607-8438 (online) |
|
dc.identifier.other |
10.3109/03008207.2014.989320 |
|
dc.identifier.uri |
http://hdl.handle.net/2263/45782 |
|
dc.language.iso |
en |
en_ZA |
dc.publisher |
Informa Healthcare |
en_ZA |
dc.rights |
© Informa Healthcare. This is an electronic version of an article published in Connective Tissue Research, vol. 56, no. 3, pp. 195-203, 2015. doi : 10.3109/03008207.2014.989320. Connective Tissue Research is available online at : http://informahealthcare.com/journal/cts |
en_ZA |
dc.subject |
Eugenol |
en_ZA |
dc.subject |
RAW264.7 macrophages |
en_ZA |
dc.subject |
Osteoclast |
en_ZA |
dc.subject |
RANKL |
en_ZA |
dc.subject |
NFκB pathway |
en_ZA |
dc.subject |
MAPK pathway |
en_ZA |
dc.subject |
Receptor activator of NF-κB ligand (RANKL) |
en_ZA |
dc.subject |
Mitogen-activated protein kinase pathways (MAPK) |
en_ZA |
dc.title |
Inhibitory effects of eugenol on RANKL-induced osteoclast formation via attenuation of NF-kappa B and MAPK pathways |
en_ZA |
dc.type |
Postprint Article |
en_ZA |